| Literature DB >> 16682682 |
A J M Ferreri1, S Dell'Oro, M Foppoli, M Bernardi, A A Brandes, A Tosoni, M Montanari, M Balzarotti, M Spina, F Ilariucci, F Zaja, C Stelitano, F Bobbio, G Corazzelli, L Baldini, M Ponzoni, P Picozzi, F Caligaris Cappio, M Reni.
Abstract
The authors assessed MATILDE chemotherapy followed by response-tailored radiation therapy in 41 patients aged 70 years or younger with primary CNS lymphoma in a Phase II trial. With response rates of 76% after MATILDE and 83% after chemotherapy with or without radiation therapy, this was an active strategy, particularly in low- to intermediate-risk patients (International Extranodal Lymphoma Study Group [IELSG] score). Myelosuppression was the dose-limiting toxicity, with 9.5% of lethal complications. After a median follow-up of 49 months, a plateau in the survival curve (5-year overall survival: 41 +/- 7%) was obtained.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16682682 DOI： 10.1212/01.wnl.0000210464.94122.e1
Source DB: PubMed Journal: Neurology ISSN： 0028-3878 Impact factor: 9.910